Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2020-05-26 Regulatory Filings
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Notice of meeting - English.pdf
Regulatory Filings
2020-05-26 English
News release - English.pdf
Regulatory Filings
2020-05-15 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-05-15 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2020-05-15 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing that Trillium Therapeutics will present data on their CD47 blocker TTI-622 at the ASCO20 Virtual Scientific Program. It includes details about the presentation, session, and availability of the poster. There is no financial data, no regulatory filing, no report attached or referenced as being published, and no mention of shareholder votes, management changes, or other regulatory matters. The content is primarily an investor presentation announcement about upcoming scientific data presentation. Given the nature of the document as a presentation announcement and the detailed description of the presentation, the most appropriate classification is Investor Presentation (IP). The document length is short and it is not a full report but an announcement of a presentation event, which fits the Investor Presentation category best rather than Report Publication Announcement or Regulatory Filings.
2020-05-13 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the establishment of an "at-the-market" equity program by Trillium Therapeutics. It details the sales agreement for common shares, the intended use of proceeds, and references a prospectus supplement filed with the SEC. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document focuses on a financing activity (equity program) and is an announcement rather than a full report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5148 characters, sufficient for a detailed announcement but not a full financial report.
2020-05-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.